World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
83
Citations
44662
World Ranking
15355
National Ranking
7743

Robert D. Toto publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Robert D. Toto sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 293 publications — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Robert D. Toto D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Robert D. Toto sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 83 D-Index — 24th percentile

24% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Robert D. Toto is affiliated with The University of Texas Southwestern Medical Center in the United States. Their research primarily spans the field of Medicine with a strong focus on Endocrinology, Diabetes and Metabolism, Nephrology, and Surgery. Additional areas of study include Cardiology and Cardiovascular Medicine and Molecular Biology.

Their work covers several prominent topics including Diabetes Treatment and Management, Chronic Kidney Disease and Diabetes, Pancreatic function and diabetes, Renal Diseases and Glomerulopathies, Diabetes Management and Research, Acute Kidney Injury Research, and Hormonal Regulation and Hypertension.

Robert D. Toto has contributed to multiple research articles published in well-known scientific venues. Frequent publication venues include:

  • Journal of the American Society of Nephrology
  • Nephrology Dialysis Transplantation
  • Kidney International Reports
  • bioRxiv (Cold Spring Harbor Laboratory)
  • Kidney International

Some recent notable papers authored or co-authored by Robert D. Toto are:

  • An atlas of healthy and injured cell states and niches in the human kidney, 2023, Nature
  • Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial, 2020, The Lancet Diabetes & Endocrinology
  • A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy, 2021, Kidney International
  • Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial, 2021, The Lancet Diabetes & Endocrinology
  • The dapagliflozin and prevention of adverse outcomes in chronic kidney disease (DAPA-CKD) trial: baseline characteristics, 2020, Nephrology Dialysis Transplantation

Robert D. Toto's frequent collaborators include:

  • Peter Rossing
  • Glenn M. Chertow
  • Hiddo J.L. Heerspink
  • John J.V. McMurray
  • David C. Wheeler

Best Publications

  • Dapagliflozin in Patients with Chronic Kidney Disease

    Hiddo J.L. Heerspink;Bergur V. Stefánsson;Ricardo Correa-Rotter;Glenn M. Chertow

  • A Trial of Darbepoetin Alfa in Type 2 Diabetes and Chronic Kidney Disease

    Marc A Pfeffer;Emmanuel A. Burdmann;Chao Yin Chen;Mark E. Cooper

  • Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: Results from the AASK trial

    Jackson T. Wright;George Bakris;Tom Greene;Larry Y. Agodoa

  • Effect of Dialysis Dose and Membrane Flux in Maintenance Hemodialysis

    Garabed Eknoyan;Gerald J. Beck;Alfred K. Cheung;John T. Daugirdas

  • Preserving renal function in adults with hypertension and diabetes: A consensus approach

    George L. Bakris;Mark Williams;Lance Dworkin;William J. Elliott

  • Sympathetic overactivity in patients with chronic renal failure.

    Richard L. Converse;Tage N. Jacobsen;Robert D. Toto;Charles M T Jost

  • Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis

    Tazeen H. Jafar;Paul C. Stark;Christopher H. Schmid;Marcia Landa

  • Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data

    T. H. Jafar;C. H. Schmid;M. Landa;I. Giatras

  • Bardoxolone Methyl and Kidney Function in CKD with Type 2 Diabetes

    Pablo E. Pergola;Philip Raskin;Robert D. Toto;Colin J. Meyer

  • Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial.

    L. Y. Agodoa;L. Appel;G. L. Bakris;G. Beck

  • Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.

    Julio Rosenstock;Vlado Perkovic;Odd Erik Johansen;Mark E. Cooper

  • Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease

    Dick de Zeeuw;Tadao Akizawa;Paul Audhya;George L. Bakris

  • Intensive blood-pressure control in hypertensive chronic kidney disease.

    Lawrence J. Appel;Jackson T. Wright;Tom Greene;Lawrence Y. Agodoa

  • Cardiac diseases in maintenance hemodialysis patients: results of the HEMO Study.

    Alfred K. Cheung;Mark J. Sarnak;Guofen Yan;Michael Berkoben

  • The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

    William F. Keane;Barry M. Brenner;Dick de Zeeuw;Jean-Pierre Grunfeld

  • Proteinuria and other markers of chronic kidney disease: a position statement of the national kidney foundation (NKF) and the national institute of diabetes and digestive and kidney diseases (NIDDK).

    Garabed Eknoyan;Thomas Hostetter;Thomas Hostetter;George L. Bakris;George L. Bakris;Lee Hebert;Lee Hebert

  • Erythropoietic response and outcomes in kidney disease and type 2 diabetes

    Scott D. Solomon;Hajime Uno;Eldrin F. Lewis;Kai Uwe Eckardt

  • Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

    David C Wheeler;David C Wheeler;Bergur V Stefánsson;Niels Jongs;Glenn M Chertow

  • Paradoxical withdrawal of reflex vasoconstriction as a cause of hemodialysis-induced hypotension.

    Richard L. Converse;Tage N. Jacobsen;Charles M T Jost;Robert D. Toto

  • Association between Chronic Kidney Disease and Coronary Artery Calcification: The Dallas Heart Study

    Holly Kramer;Robert D Toto;Ronald M Peshock;Richard Cooper

Frequent Co-Authors

Scott M. Grundy
Scott M. Grundy The University of Texas Southwestern Medical Center
Bernard P. Halloran
Bernard P. Halloran University of California, San Francisco
Jorge H. Capdevila
Jorge H. Capdevila Vanderbilt University
Ronald G. Victor
Ronald G. Victor Cedars-Sinai Medical Center
Paul A. Grayburn
Paul A. Grayburn Baylor University Medical Center
Rajiv Agarwal
Rajiv Agarwal Indiana University – Purdue University Indianapolis

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For students interested in alternative healthcare career pathways beyond the traditional MD, online degrees offer flexible ways to advance your education in the U.S. Nursing is a popular choice, with online programs for both entry-level and experienced learners. For example, you can explore an online lpn program to quickly enter the nursing field or move forward with an rn to bsn with no clinicals program designed for busy registered nurses. These options help streamline the path to advanced roles with minimal disruption to your current work schedule.

For nurses aiming to reach the highest levels, there are also dnp online programs that can be completed on an accelerated timeline. Those seeking less rigorous pathways may benefit from exploring easy dnp programs that still provide the leadership and clinical skills needed for top-tier positions. These online degrees offer flexible, reputable routes to fulfilling health careers without the extended commitment of a traditional medical degree.

Best Scientists Citing Robert D. Toto

Trending Scientists

Recently Published Articles